Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 28-29

  Puccetti, Luca ^a   Ciani, Federica ^b   Auteri, Alberto ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN;

CASE CONTROL STUDY; CREATINE KINASE BLOOD LEVEL; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FAMILIAL HYPERCHOLESTEROLEMIA; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HUMAN; LETTER; MUSCLE CRAMP; MYOPATHY; OBSERVATIONAL STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; CHEMICALLY INDUCED; FEMALE; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUSCLE DISEASE;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUSCULAR DISEASES; ORGANIC ANION TRANSPORTERS;

EID: 77954310138     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.02.026     Document Type: Letter

References (9)

1. Baigent C., Keech A., Kearney P.M., et al. Efficacy and Safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1268.
2. Ho P.M., Magid Dj, Shetterly S.M., et al. Medication nonadherence is associated with a broad range of diverse outcomes in patients with coronary artery disease. Am Heart J 2008, 155:772-779.
3. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008, 359:789-799.
4. Voora D., Svati H.S., Spasojevic I., et al. The SLCO1B1*5 genetic variants associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616.
5. Golomb B.A., Evans M.A. Statin adverse effects. A review of the literature and evidence for a mitochondrial mechanisms. Am J Cardiovasc drugs 2008, 8:373-418.
6. Knauer M.J., Urquhart B.L., Meyer Z., et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010, 106:297-306.
7. Oh J., Ban M.R., Miskie B.A., et al. Genetic determinants of statin intolerance. Lipids Health Dis 2007, 6:7.
8. Puccetti L., Pasqui A.L., Pastorelli M., et al. 3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects. Atherosclerosis 2005, 183:322-328.
9. Pasanen M.K., Fredrikson H., Neuvonen P.J., Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007, 82:726-733.